NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

9473	Companies
185388	Keywords
117743	Articles
99274	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 11/05/2025 at 14:30, 29 days 18 hours ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
NanoViricides, Inc. announces Annual Shareholders Meeting to discuss progress on NV-387, a potential treatment for MPox Clade I. Clinical trials underway

NV-387 Clinical Trials NanoViricides Inc. Annual Shareholders Meeting Mpox Clade I
BRIEF

published on 11/03/2025 at 14:35, 1 month 1 day ago

NanoViricides présentera ses produits à la conférence des investisseurs de Spartan Capital en 2025.

NanoViricides NV-387 Essais Cliniques Médicaments Antiviraux Conférence De La Capitale Spartiate
BRIEF

published on 11/03/2025 at 14:35, 1 month 1 day ago

NanoViricides to Present at Spartan Capital Investor Conference 2025

NanoViricides NV-387 Clinical Trials Antiviral Drugs Spartan Capital Conference
PRESS RELEASE

published on 11/03/2025 at 14:30, 1 month 1 day ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
NanoViricides, Inc. to present groundbreaking antiviral drug NV-387 at Spartan Capital Investor Conference. CEO Diwan to update on drug pipeline & Platform Technologies for licensing

NanoViricides NV-387 Clinical Trial Antiviral Drug Spartan Capital Investor Conference
BRIEF

published on 10/29/2025 at 13:50, 1 month 6 days ago

NV-387 : un agent antiviral prometteur contre la rougeole

NanoViricides NV-387 Essais Cliniques Recherche Antivirale Traitement De La Rougeole
BRIEF

published on 10/29/2025 at 13:50, 1 month 6 days ago

NV-387: A Promising Antiviral Agent for Measles

NanoViricides NV-387 Clinical Trials Antiviral Research Measles Treatment
PRESS RELEASE

published on 10/29/2025 at 13:45, 1 month 6 days ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
NanoViricides, Inc. announced progress in antiviral research with their drug NV-387 showing potent activity against Measles virus. Clinical trials have shown safety and effectiveness, positioning for emergency use

NanoViricides NV-387 Clinical Trials Antiviral Research Measles Virus
BRIEF

published on 10/27/2025 at 13:50, 1 month 8 days ago

NanoViricides sera présenté à la conférence PODD 2025

NanoViricides NV-387 Biotechnologie Essais Cliniques Médicament Antiviral
BRIEF

published on 10/27/2025 at 13:50, 1 month 8 days ago

NanoViricides Set to Present at PODD 2025 Conference

NanoViricides NV-387 Biotechnology Clinical Trials Antiviral Drug
PRESS RELEASE

published on 10/27/2025 at 13:45, 1 month 8 days ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
NanoViricides, Inc. to present at PODD 2025 Conference with focus on revolutionary broad-spectrum antiviral drugs in development for various viral infections

Respiratory Viral Infections NV-387 Antiviral Drugs NanoViricides, Inc. PODD 2025 Conference

Accesswire

Published on 12/05/2025 at 02:35, 5 hours 57 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 6 hours 2 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 7 hours 32 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 9 hours 27 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 32 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 08:05, 27 minutes ago

Smartmi Unveils the Air Purifier 3: Powerful, Smart, and Stylish Air Care for Modern Homes
Published on 12/05/2025 at 08:01, 31 minutes ago

Original-Research: Warimpex Finanz- und Beteiligungsholding AG (von East Value Research GmbH ):
Published on 12/05/2025 at 08:01, 31 minutes ago

Custodian Property Income REIT plc: Interim results for the period ended 30 September 2025
Published on 12/05/2025 at 08:00, 32 minutes ago

Swiss Prime Site Solutions Investment Fund Commercial (SPSS IFC) approaches the 500-million mark ahead of listing
Published on 12/05/2025 at 08:00, 32 minutes ago

Le Swiss Prime Site Solutions Investment Fund Commercial (SPSS IFC) croît et est sur le point de franchir la barre des 500 millions

Les Echos

Published on 12/04/2025 at 18:14, 14 hours 17 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 14 hours 32 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 14 hours 32 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 47 minutes ago

Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 14 hours 47 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE